Cited 0 times in
SKYSCRAPER-07: A phase III, randomized, double-blind, placebo-controlled study of atezolizumab with or without tiragolumab in patients with unresectable ESCC who have not progressed following definitive concurrent chemoradiotherapy
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.